By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AMAG Pharmaceuticals, Inc. 

1100 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 617-498–3300 Fax: 617-499-3361


Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.

AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.

Key Statistics

Ownership: Public

Web Site: AMAG
Employees: 51-200
Symbol: AMAG


Company News
AMAG (AMAG) Appoints Oscar Sanchez As Vice President Of Quality 8/8/2017 12:41:46 PM
AMAG (AMAG) Announces Second Quarter 2017 Financial Results And Provides Corporate Update 8/3/2017 1:28:28 PM
AMAG (AMAG) Completes Feraheme (Ferumoxytol) FDA Submission For The Treatment Of All Adult Patients With Iron Deficiency Anemia 8/3/2017 11:48:58 AM
AMAG (AMAG) Launches Intrarosa (Prasterone) In The U.S. – A Novel Product To Treat Moderate To Severe Dyspareunia Due To Menopause 7/24/2017 10:17:14 AM
AMAG (AMAG) To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Thursday, August 3, 2017 At 8:00 A.M. ET 7/20/2017 11:41:57 AM
AMAG (AMAG) Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Makena® (Hydroxyprogesterone Caproate Injection) Subcutaneous Auto-Injector 6/26/2017 9:54:59 AM
AMAG (AMAG) Announces First Patient Enrolled In Phase IIb/IIIa Digoxin Immune Fab Study Conducted By Velo Bio 6/1/2017 11:29:45 AM
AMAG (AMAG) Appoints Helen Milton, Ph.D. As Vice President Of Regulatory Affairs 5/16/2017 10:40:45 AM
AMAG (AMAG) Completes Financing Transactions In Support Of Future Growth Strategy 5/15/2017 8:11:01 AM
AMAG (AMAG) To Host Analyst Day On May 24th In New York 5/10/2017 10:02:14 AM